-
公开(公告)号：US06899915B2
公开(公告)日：2005-05-31
申请号：US09997734
申请日：2001-11-29
CPC分类号： A61L27/3804 , A61K6/087 , A61K6/10 , A61L27/18 , A61L27/3865 , C08L67/04 , C08L51/085
摘要： Tooth tissues include the pulp mesenchyme that forms the dentin and an epithelium that is responsible for enamel formation. Cells from these tissues were obtained from porcine third molars and were seeded onto a biodegradable scaffold composed of a polyglycolic acid—polylactic acid copolymer. Cell polymer constructs were then surgically implanted into the omentum of athymic nude rats so that the constructs would have a blood supply and these tissues were allowed to develop inside the rats. Infrequently, columnar epithelial cells were observed as a single layer on the outside of the dentin-like matrix similar to the actual arrangement of ameloblasts over dentin during early tooth development. Developing tooth tissues derived from such cell polymer constructs could eventually be surgically implanted into the gum of an edentulous recipient where the construct would receive a blood supply and develop to maturity, providing the recipient with a biological tooth replacement.
摘要翻译： 牙组织包括形成牙本质的牙髓间质和负责牙釉质形成的上皮。 来自这些组织的细胞从猪第三磨牙获得，并且接种到由聚乙醇酸 - 聚乳酸共聚物组成的可生物降解的支架上。 然后将细胞聚合物构建体手术植入无胸腺裸鼠的网膜中，使得构建体将具有血液供应，并且允许这些组织在大鼠内部发育。 不常见的是，柱状上皮细胞在牙质样基质的外侧被看作单层，类似于早期牙齿发育过程中釉质在牙本质上的实际布置。 来自这样的细胞聚合物构建体的牙齿组织的发育最终可以被手术植入无牙细胞受体的牙龈中，其中构建体将接受血液供应并发育成熟，从而为受体提供生物牙齿置换。
-
2.发明申请Use of Stem Cells, Method of Tissue Engineering, Use of Dental Tissues and Tooth Biological Substitute 审中-公开干细胞的使用，组织工程方法，牙齿组织和牙齿生物学替代品的使用公开(公告)号：US20090029322A1
公开(公告)日：2009-01-29
申请号：US11630476
申请日：2005-06-23
CPC分类号： C12N5/0664 , A61L27/3804 , A61L27/3865 , C12N2533/54
摘要： The present invention is related to the use of stem cells of an animal species for obtainment of biological tooth substitute, in whole or in parts, to be implanted in organism of the same animal strain, wherein said stem cells can be adult cells. The present invention still aims to develop a method of tissue engineering for culturing cells capable to form dental tissue for production of a tooth biological substitute. The said dental tissue can used for the treatment of people suffering from loss, fail or lack of these tissues, and also for cosmetic use of those tissues for a morphological modifying on a patient dentition, for example, the patient may desire to, or need to, have a bigger or smaller dentition for any aesthetic reason.
摘要翻译： 本发明涉及将动物物种的干细胞用于获得全部或部分生物学牙齿替代物植入相同动物菌株的生物体中的用途，其中所述干细胞可以是成体细胞。 本发明的目的还在于开发一种用于培养能够形成用于生产牙齿生物学替代物的牙科组织的细胞的组织工程方法。 所述牙齿组织可用于治疗患有这些组织损失，失败或缺乏的人，以及用于对患者牙列进行形态学修饰的那些组织的化妆品使用，例如患者可能希望或需要 具有任何美学原因的更大或更小的牙列。
-
3.发明授权Nanotopographic compositions and methods for cellular organization in tissue engineered structures 有权组织工程结构中的细胞组织的纳米形成组合物和方法公开(公告)号：US08865466B2
公开(公告)日：2014-10-21
申请号：US13350749
申请日：2012-01-14
CPC分类号： A61L27/3886 , A61L27/50 , B33Y80/00 , C12N5/0075 , C12N5/067 , C12N2535/10
摘要： The present invention relates to tissue engineered compositions and methods comprising nanotopographic surface topography (“nanotopography”) for use in modulating the organization and/or function of multiple cell types.
摘要翻译： 本发明涉及包含用于调节多种细胞类型的组织和/或功能的纳米形态表面形貌（“纳米形貌”）的组织工程化组合物和方法。
-
公开(公告)号：US08491561B2
公开(公告)日：2013-07-23
申请号：US12857489
申请日：2010-08-16
申请人： Jeffrey T. Borenstein , Eli Weinberg , Brian K. Orrick , Eleanor M. Pritchard , Edward J. Barnard , Nicholas J. Krebs , Theodore Marentis , Joseph P. Vacanti , Mohammad Reza Kaazempur-Mofrad
发明人： Jeffrey T. Borenstein , Eli Weinberg , Brian K. Orrick , Eleanor M. Pritchard , Edward J. Barnard , Nicholas J. Krebs , Theodore Marentis , Joseph P. Vacanti , Mohammad Reza Kaazempur-Mofrad
IPC分类号： C12M3/06
CPC分类号： A61M1/1678 , Y10T436/25375 , Y10T436/255
摘要： Methods and materials for making an apparatus which duplicates the functionality of a physiological system is provided.
摘要翻译： 提供了用于制造复制生理系统的功能的装置的方法和材料。
-
公开(公告)号：US08173361B2
公开(公告)日：2012-05-08
申请号：US12707469
申请日：2010-02-17
IPC分类号： C12Q1/00
CPC分类号： C12Q1/48 , B33Y80/00 , C12Q1/00 , C12Q1/18 , C12Q1/26 , C12Q1/34 , C12Q1/42 , C12Q1/44 , G01N33/5038 , G01N33/5088
摘要： A method for detecting one or more metabolites of a test agent in a tissue including: A) incubating a test agent and an enzyme within a three-dimensional structure comprising a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, and wherein the first mold or polymer scaffold has microchannels that form a fluidic branching network that mimics the forces and transport of natural vasculatures and wherein the second mold or polymer scaffold comprises cells; B) forming an enzyme-substrate complex between the enzyme and the test agent; and C) detecting one or more metabolites of the test agent.
摘要翻译： 一种用于检测组织中测试剂的一种或多种代谢物的方法，包括：A）将测试试剂和酶在三维结构内孵育，所述三维结构包括第一模具或聚合物支架，半透膜和第二模具 或聚合物支架，其中所述半透膜设置在所述第一和第二模具或聚合物支架之间，并且其中所述第一模具或聚合物支架具有微通道，所述微通道形成模拟天然脉管系统的力和运输的流体分支网络，并且其中 第二模具或聚合物支架包括细胞; B）在酶和试验剂之间形成酶 - 底物复合物; 和C）检测试剂的一种或多种代谢物。
-
公开(公告)号：USRE42479E1
公开(公告)日：2011-06-21
申请号：US10782750
申请日：2004-02-19
IPC分类号： A61F2/24
CPC分类号： A61L27/3886 , A61F2/2415 , A61L27/18 , A61L27/3633 , A61L27/3645 , A61L27/3804 , A61L27/3843 , A61L27/507 , A61L27/58 , C08L67/04
摘要： It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.
-
7.发明授权Microfabricated compositions and processes for engineering tissues containing multiple cell types 有权包含多种细胞类型的工程组织的微型组合物和方法公开(公告)号：US07960166B2
公开(公告)日：2011-06-14
申请号：US10557081
申请日：2004-05-21
IPC分类号： C12M1/14
CPC分类号： C12N5/0068 , B33Y80/00 , C12N5/0062 , C12N5/0697 , C12N2533/40
摘要： The present invention relates to a three-dimensional system, and compositions obtained therefrom, wherein individual layers of the system comprise channels divided longitudinally into two compartments by a centrally positioned membrane, and wherein each compartment can comprise a different cell type.
摘要翻译： 本发明涉及一种三维体系及其组合物，其中系统的各层包括通过中心定位的膜纵向分成两个隔室的通道，并且其中每个隔室可包括不同的细胞类型。
-
8.发明申请公开(公告)号：US20110008765A1
公开(公告)日：2011-01-13
申请号：US12707469
申请日：2010-02-17
申请人： Joseph P. Vacanti , Robert Rubin , Wing Cheung
发明人： Joseph P. Vacanti , Robert Rubin , Wing Cheung
CPC分类号： C12Q1/48 , B33Y80/00 , C12Q1/00 , C12Q1/18 , C12Q1/26 , C12Q1/34 , C12Q1/42 , C12Q1/44 , G01N33/5038 , G01N33/5088
摘要： The present invention generally relates to a combination of the fields of tissue engineering, drug discovery and drug development. It more specifically provides new methods and materials for testing the efficacy and safety of experimental drugs, defining the metabolic pathways of experimental drugs and characterizing the properties (e.g., side effects, new uses) of existing drugs. Preferably, evaluation is carried out in three-dimensional tissue-engineered systems, wherein drug toxicity, metabolism, interaction and/or efficacy can be determined.
摘要翻译： 本发明一般涉及组织工程，药物发现和药物开发领域的组合。 它更具体地提供了用于测试实验药物的功效和安全性，定义实验药物的代谢途径和表征现有药物的性质（例如副作用，新用途）的新方法和材料。 优选地，在三维组织工程系统中进行评价，其中可以确定药物毒性，代谢，相互作用和/或功效。
-
公开(公告)号：US07670797B2
公开(公告)日：2010-03-02
申请号：US11183115
申请日：2005-07-15
IPC分类号： C12Q1/24
CPC分类号： C12Q1/48 , B33Y80/00 , C12Q1/00 , C12Q1/18 , C12Q1/26 , C12Q1/34 , C12Q1/42 , C12Q1/44 , G01N33/5038 , G01N33/5088
摘要： A method of determining toxicity of a test agent in a tissue including A) incubating a test agent within a three-dimensional tissue engineered structure comprising a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, and wherein the first mold or polymer scaffold has microchannels comprising vessels that bifurcate, and B) obtaining information from step A) to assess toxicity.
摘要翻译： 一种测定试剂在组织中的毒性的方法，包括A）在包含第一模具或聚合物支架，半透膜和第二模具或聚合物支架的三维组织工程结构内温育试验剂，其中 半透膜设置在第一和第二模具或聚合物支架之间，并且其中第一模具或聚合物支架具有包含分叉的容器的微通道，以及B）从步骤A）获得信息以评估毒性。
-
公开(公告)号：US07462471B2
公开(公告)日：2008-12-09
申请号：US10775768
申请日：2004-02-10
申请人： Antonios G. Mikos , Joseph P. Vacanti , Robert S. Langer , Linda G. Griffith , Georgios Sarakinos
发明人： Antonios G. Mikos , Joseph P. Vacanti , Robert S. Langer , Linda G. Griffith , Georgios Sarakinos
CPC分类号： G02B27/0031 , A61L27/18 , A61L27/56 , A61L2400/06 , G03F7/40 , H01L21/0273 , H01L21/32139 , C08L67/04
摘要： Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.
摘要翻译： 聚合材料用于制造一种柔韧，无毒，可注射的多孔模板，用于血管向内生长。 通常在约100和300微米之间的孔径允许血管和结缔组织在植入后约10至90％的基质向内生长，并且在整个植入的基质中均匀注射细胞而不损伤细胞或患者。 引入的细胞附着到基质内的结缔组织，并由血管进食。 用于形成基质或支撑结构的优选材料是生物相容的合成聚合物，其通过水解以受控的方式降解成无害的代谢物，例如聚乙醇酸，聚乳酸，聚原酸酯，聚酐或其共聚物。 随着植入装置的孔隙率和/或孔径增加，组织向内生长的速率增加。 组织填充装置所需的时间取决于聚合物的结晶度，对于无定形聚合物与半结晶聚合物相比较少。 前进组织的血管分布与时间一致，与生物材料组成和形态无关。
-
-
-
-
-
-
-
-
-
搜索结果
67 条记录 (耗时 0.047 秒)
